Chinese biopharma firm Waterstone raises $61m Series C round

Chinese biopharmaceutical firm Waterstone Pharmaceuticals has raised 420 million yuan ($61 million) in a Series C round of financing led by SDIC JULI Investment Management, an equity investment fund co-launched by China’s state-owned investment giant SDIC.